Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis

Journal of Bone and Mineral Research

Volumn 17, Issue 11, 2002, Pages 1988-1996

  Rizzoli, Rene ^a  

^a Hôpital Cantonal   (Switzerland)

Author keywords

Alendronate; Bone mass; Once weekly dosing; Osteoporosis

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; COLLAGEN TYPE 1;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE MASS; BONE MINERAL; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DUODENUM PERFORATION; DUODENUM ULCER; FEMALE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OSTEOLYSIS; OSTEOPOROSIS; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; STOMACH PERFORATION;

ADULT; AGED; AGED, 80 AND OVER; ALENDRONATE; ALKALINE PHOSPHATASE; BONE DENSITY; BONE RESORPTION; COLLAGEN; COLLAGEN TYPE I; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FRACTURES, BONE; GASTROINTESTINAL DISEASES; HUMANS; LUMBAR VERTEBRAE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PEPTIDES; TREATMENT OUTCOME;

EID: 0036828449     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.2002.17.11.1988     Document Type: Article

References (33)

1. Greenberg RN 1984 Overview of patient compliance with medication dosing: A literature review. Clin Ther 6:592-599.
2. Lau HS, Beuning KS, Postma-Lim E, Klein-Beernink L, de Boer A, Porsius AJ 1996 Non-compliance in elderly people: Evaluation of risk factors by longitudinal data analysis. Pharm World Sci 18:63-68.
3. Venturini F, Nichol MB, Sung JC, Bailey KL, Cody M, McCombs JS 1999 Compliance with sulfonylureas in a health maintenance organization: A pharmacy record-based study. Ann Pharmacother 33:281-288.
4. Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW, Dequeker J, Favus M, Seeman E, Recker RR, Capizzi T, Santora A, Lombardi A, Shah RV, Hirsch LJ, Karpf DB 1995 Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 333:1437-1443.
5. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Tomer JC, Quandt SA, Reiss TF, Ensrud KE 1996 Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348:1535-1541.
6. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ 1998 Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. JAMA 280:2077-2082.
7. Pols HAP, Felsenberg D, Hanley DA, Stepan J, Monoz-Torres M, Wilkin TJ, Qin-sheng G, Galich AM, Vandormael K, Yates AJ, Stych B 1999 Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: Results of the FOSIT study. Osteoporos Int 9:461-468.
8. Hochberg M, Ross PD, Black D, Cummings SR, Genant HK, Nevitt MC, Barrett-Connor E, Musliner T, Thompson D 1999 Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Arthritis Rheum 42:1246-1254.
9. Bauer DC, Black D, Ensrud K, Thompson D, Hochberg M, Nevitt M, Musliner T, Freedholm D 2000 Upper gastrointestinal tract safety profile of alendronate: The Fracture Intervention Trial. Arch Intern Med 160:517-525.
10. Bone HG, Adami S, Rizzoli R, Favus M, Ross PD, Santora A, Prahalada S, Daifotis A, Orloff J, Yates J 2000 Weekly administration of alendronate: Rationale and plan for clinical assessment. Clin Ther 22:15-28.
11. Schnitzer T, Bone HG, Crepaldi G, Adami S, McClung M, Kiel D, Felsenberg D, Recker RR, Tonino RP, Roux C, Pinchera A, Foldes AJ, Greenspan SL, Levine MA, Emkey R, Santora AC, Kaur A, Thompson DE, Yates J, Orloff JJ 2000 Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Aging Clin Exp Res 12:1-12.
12. Black DM, Palermo L, Nevitt MC, Genant HK, Epstein R, San Valentin R, Cummings SR 1995 Comparison of methods for defining prevalent vertebral deformities: The study of osteoporotic fractures. J Bone Miner Res 10:890-902.
13. Faulkner KG, McClung MR 1995 Quality control of DXA instruments in multicenter trials. Osteoporos Int 5:218-227.
14. ICH Harmonised Tripartite Guideline 1999 Statistical principles for clinical trials. International Conference on Harmonisation E9 Expert Working Group. Stat Med 18:1905-1942.
15. Génant HK, Wu CY, van Kuijk C, Nevitt MC 1993 Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8:1137-1148.
16. Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, Nevitt MC, Suryawanshi S, Cummings SR 2000 Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial. J Clin Endocrinol Metab 85:4118-4124.
17. Thompson D 2000 Consistency of effect of alendronate on reduction in risk of hip fractures. J Am Geriatr Soc 48:S56 (abstract).
18. Faulkner KG 2000 Bone matters: Are density increases necessary to reduce fracture risk? J Bone Miner Res 15:183-187.
19. Garnero P, Hausherr E, Chapuy M-C, Marcelli C, Grandjean H, Muller C, Cormier C, Breart G, Meunier PJ, Delmas PD 1996 Markers of bone resorption predict hip fracture in elderly women: The EPIDOS prospective study. J Bone Miner Res 11:1531-1538.
20. Riis BJ, Hansen AM, Overgaard JK, Christiansen C 1996 Low bone mass and fast rate of bone loss at menopause: Equal risk factors for future fracture: A 15-year follow-up study. Bone 19:9-12.
21. Harris ST, Watts NB, Jackson RD, Genant HK, Wasnich RD, Ross P, Miller PD, Licata AA, Chesnut CH 1993 Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: Three years of blinded therapy followed by one year of open therapy. Am J Med 95:557-567.
22. Recker RR, Stakkestad JA, Felsenberg D, Chesnut CH, Christiansen C, Ettinger MP, Nordby A, Weiss SR, Huss H, Von Stein T, Karpf DB 2000 A new treatment paradigm: Quarterly injections of ibandronate reduce the risk of fractures in women with postmenopausal osteoporosis (PMO): Results of a 3-year trial. Osteoporos Int 11:S209 (abstract).
23. Chesnut CH, McClung MR, Ensrud KE, Bell NH, Genant HK, Harris ST, Singer FR, Stock JL, Yood RA, Delmas PD, Kher U, Pryor-Tillotson S, Santora AC 1995 Alendronate treatment of the postmenopausal osteoporotic woman: Effect of multiple dosages on bone mass and bone remodeling. Am J Med 99:144-152.
24. Devogelaer JP, Broll H, Correa-Rotter R, Cumming DC, De Deuxchaisnes CN, Geusens P, Hosking D, Jaeger P, Kaufman JM, Leite M, Leon J, Liberman U, Menkes CJ, Meunier PJ, Reid I, Rodriguez J, Romanowicz A, Seeman E, Vermeulen A, Hirsch LJ, Lombardi A, Plezia K, Santora AC, Yates AJ, Yuan W 1996 Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis. Bone 18:141-150.
25. Adami S, Passeri M, Ortolani S, Broggini M, Carratelli L, Caruso I, Gandolini G, Gnessi L, Laurenzi M, Lombardi A, Norbiato G, Pryor-Tillotson S, Reda C, Romanini L, Subrizi D, Wei L, Yates AJ 1995 Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis. Bone 17:383-390.
26. Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD 1994 Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 79:1693-1700.
27. Bone H, Schnitzer T, Reid I, Adami S, Miller P, Kaur A, Snodgrass S, Orloff JJ 2002 Once-weekly alendronate 70 mg: Sustained suppression of bone resorption. Osteoporos Int 13: S29 (abstract).
28. Chavassieux PM, Arlot ME, Reda C, Wei L, Yates AJ, Meunier PJ 1997 Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 100:1475-1480.
29. Seedor JG, Quartuccio HA, Thompson DD 1991 The bisphosphonate alendronate (MK-217) inhibits bone loss due to ovariectomy in rats. J Bone Miner Res 6:339-346.
30. Balena R, Toolan BC, Shea M, Markatos A, Myers ER, Lee SC, Opas EE, Seedor JG, Klein H, Frankenfield D, Quartuccio H, Fioravanti C, Clair J, Brown E, Hayes WC, Rodan GA 1993 The effect of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates. J Clin Invest 92:2577-2586.
31. DeGroen PC, Lubbe DF, Hirsch LJ, Daifotis A, Stephenson W, Freedholm D, Pryor-Tillotson S, Seleznick MJ, Pinkas H, Wang KK 1996 Esophagitis associated with the use of alendronate. N Engl J Med 335:1016-1021.
32. Reginster J-Y, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R 2000 Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 11:83-91.
33. Peter CP, Handt LK, Smith SM 1998 Esophageal irritation due to alendronate sodium tablets: Possible mechanisms. Dig Dis Sci 43:1998-2002.